VolitionRX Limited (NYSEAMERICAN:VNRX) Short Interest Update

VolitionRX Limited (NYSEAMERICAN:VNRX) was the target of a large decrease in short interest during the month of June. As of June 15th, there was short interest totaling 254,125 shares, a decrease of 34.7% from the May 31st total of 389,005 shares. Currently, 3.2% of the shares of the stock are sold short. Based on an average trading volume of 424,498 shares, the short-interest ratio is currently 0.6 days.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on VNRX. Maxim Group reiterated a “buy” rating and issued a $4.00 price objective on shares of VolitionRX in a research report on Thursday, June 18th. HC Wainwright lowered their target price on VolitionRX from $30.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, April 2nd. Citigroup cut VolitionRX to a “hold” rating in a report on Monday, April 20th. D. Boral Capital reiterated a “hold” rating on shares of VolitionRX in a research report on Monday, April 20th. Finally, Benchmark reissued a “hold” rating on shares of VolitionRX in a report on Tuesday, June 2nd. Two research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $28.00.

Institutional Trading of VolitionRX

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC raised its holdings in VolitionRX by 166.6% during the 4th quarter. Virtu Financial LLC now owns 108,581 shares of the medical research company’s stock worth $28,000 after purchasing an additional 67,848 shares during the last quarter. Squarepoint Ops LLC bought a new stake in shares of VolitionRX during the fourth quarter worth approximately $34,000. Jane Street Group LLC bought a new stake in shares of VolitionRX during the fourth quarter worth approximately $28,000. Geode Capital Management LLC raised its stake in shares of VolitionRX by 9.8% during the fourth quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock worth $246,000 after buying an additional 85,816 shares during the last quarter. Finally, Armistice Capital LLC lifted its holdings in VolitionRX by 10.4% in the third quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock valued at $6,367,000 after buying an additional 887,351 shares during the period. 8.09% of the stock is currently owned by institutional investors and hedge funds.

VolitionRX Stock Performance

VNRX stock remained flat at $1.40 during trading on Friday. 204,280 shares of the company traded hands, compared to its average volume of 343,280. The company has a 50 day simple moving average of $2.09 and a 200-day simple moving average of $3.72. VolitionRX has a 1 year low of $1.17 and a 1 year high of $16.00. The company has a market cap of $12.08 million, a PE ratio of -0.34 and a beta of 1.12.

VolitionRX (NYSEAMERICAN:VNRX) last announced its quarterly earnings data on Thursday, May 14th. The medical research company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.27). The business had revenue of $0.99 million during the quarter, compared to analysts’ expectations of $1.52 million. Equities research analysts predict that VolitionRX will post -2.4 earnings per share for the current fiscal year.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.